Cargando…

Is chronic obstructive pulmonary disease a protective factor in SARS-CoV-2 infection? The importance of bronchodilator treatment()

Detalles Bibliográficos
Autores principales:	Boixeda, R., Campins, L., Juanola, J., Force, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519711/ https://www.ncbi.nlm.nih.gov/pubmed/32836322 http://dx.doi.org/10.1016/j.rceng.2020.07.004

Ejemplares similares

¿Es la enfermedad pulmonar obstructiva crónica un factor protector en la infección por SARS-CoV-2? La importancia del tratamiento broncodilatador
por: Boixeda, R., et al.
Publicado: (2020)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease
por: Beeh, Kai M.
Publicado: (2016)

Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important
por: Mahler, Donald A., et al.
Publicado: (2020)

Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease
por: van der Vaart, Hester, et al.
Publicado: (2011)

Tracking immune correlates of protection for emerging SARS-CoV-2 variants
por: Nilles, Eric J, et al.
Publicado: (2023)

Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua
por: Maier, Hannah E., et al.
Publicado: (2022)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection
por: Zeng, Guangting, et al.
Publicado: (2023)

Protective humoral immunity in SARS-CoV-2 infected pediatric patients
por: Zhang, Yaguang, et al.
Publicado: (2020)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Importance score of SARS-CoV-2 genome predicts the death risk of COVID-19
por: Cui, Chunmei, et al.
Publicado: (2022)

May Parkinson's disease be a protective factor against CNS involvement by SARS-CoV2?
por: Spina Tensini, F., et al.
Publicado: (2020)

Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
por: Karim, Salim S Abdool
Publicado: (2021)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Reply to Mahler et al.: Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important
por: Nici, Linda, et al.
Publicado: (2020)

The natural thermal sensitivity of SARS-CoV-2
por: Stewart, Patrick D Shaw, et al.
Publicado: (2022)

Severity Staging of Chronic Obstructive Pulmonary Disease: Differences in Pre- and Post-Bronchodilator Spirometry
por: Lin, Sheng-Hsiang, et al.
Publicado: (2009)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease
por: Shin, Hong-Joon, et al.
Publicado: (2021)

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection
por: Marking, Ulrika, et al.
Publicado: (2023)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

The importance of external quality assessment data in evaluating SARS-CoV-2 virus genome detection assays
por: Buchta, Christoph, et al.
Publicado: (2022)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease
por: Brunner, Wendy M., et al.
Publicado: (2022)

Free-floating right heart thrombus with pulmonary embolism in SARS-CoV-2 patient
por: Pla, Jordi Juanola, et al.
Publicado: (2020)

Free-floating right heart thrombus with pulmonary embolism in SARS-CoV-2 patient
por: Pla, Jordi Juanola, et al.
Publicado: (2020)

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
por: Havervall, Sebastian, et al.
Publicado: (2022)

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
por: Yoon, Sarang K., et al.
Publicado: (2022)

SARS-CoV-2 shedding and infectivity
por: Atkinson, Barry, et al.
Publicado: (2020)

The proximal origin of SARS-CoV-2
por: Andersen, Kristian G., et al.
Publicado: (2020)

SARS-CoV-2 Infection in Children
por: Lu, Xiaoxia, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence in Spain
por: George, Thukalan Paulose
Publicado: (2020)

SARS CoV2 vaccine and aphasia
por: sookaromdee, Pathum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_icltoakrtj7ag2ujden5ut6eoh